Cortalix funding news – Groningen-based Cortalix Secures €1Million in Funding

This investment marks the sixth startup in Future Tech Ventures' portfolio. The funding event was held last week at Zernike Campus, where Cortalix is based in Innolab Agrifood. It will use the funds to speed up the development and commercialisation of its single-domain antibody technology.

Herman Steen, CEO of Cortalix, says, “This investment allows us to further refine our technology and prepare it for clinical applications. Our goal is to become a leading player in nanobody-based PET imaging, radiotherapy, and immunotherapy. This funding brings us a step closer to realising that vision.”

Nanobodies are small, stable, and flexible, making them useful in cancer treatment, medical diagnostics, and other health areas. With help from Future Tech Ventures, Cortalix plans to expand its platform with libraries for radiopharmaceutical and CAR-T therapies.

This development will help make nanobodies ready for clinical use by reducing immune recognition and improving their effectiveness in treatments.

Read also - EcoDataCenter funding news – EcoDataCenter Secures €450 Million in Funding

Future Tech Ventures is an investment fund that supports high-tech startups in the early stages, focusing on the Northern Netherlands. The fund offers financing, services, and a network to help grow technology, society, and the economy.

Ignacio Faustino, investment manager at Future Tech Ventures, says, “We believe that their next-generation humanised nanobodies will provide unparalleled solutions for in vitro diagnostics and targeted therapies, which will have a significant impact on people’s health. We are proud to support Cortalix and strengthen Groningen’s position as a biotechnology hub, which perfectly aligns with our vision for the future.”

About Cortalix

Cortalix was founded in 2023 and focuses on nanobody technology and PET imaging. The company creates single-domain antibodies for PET imaging, radiotherapy, and CAR-T immunotherapy.

Their platform helps in choosing, making, and using antibody fragments as an alternative to traditional antibodies. They specialize in producing animal-free antibodies that are efficient, stable, and cost-effective, while also reducing production time.